In a phase I trial of CEA + CRC patients treated with CEA-CAR-T cells (NCT02349724), five dose-escalation CAR-T cells were administered to 10 patients with relapsed and refractory CRC metastases. The gene discussed is CEACAM5; the disease is colorectal carcinoma.